CMS issues revised ESA reimbursement instructions
Executive Summary
CMS issues formal instructions to administrative contractors on how to reimburse erythropoiesis-stimulating agents based on the national coverage decision issued July 30, 2007, restricting coverage of ESAs in the non-renal setting (1"The Pink Sheet" Aug. 6, 2007, p. 21). The updated coverage instructions were effective the day the NCD was issued and carry an implementation date of April 7, 2008. The new instructions focus on when to deny claims for non-end stage renal disease ESA treatments under HCPCS codes J0881 or J0885 billed with modifier EC (ESA, anemia, non-chemo/radio) and with modifier EA (ESA, anemia, chemo-induced) on or after Jan. 1, 2008...
You may also be interested in...
Amgen ESA Sales Dive In The Biotech’s “Toughest” Year
Sales of Amgen's Aranesp and Epogen took a hit in the fourth quarter as the safety of erythropoiesis-stimulating agents was questioned, Amgen reported during its fourth quarter and year-end earnings call Jan. 24. Going into 2008, the company will develop a risk management plan and other strategies to help address the situation
Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach
CMS has abandoned the idea of limiting some uses of erythropoiesis-stimulating agents to a research trial setting, despite receiving public comments that the "coverage with evidence development" approach may be acceptable in some circumstances
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.